Contents
07 August 2019
Vol 11, Issue 504
Vol 11, Issue 504
Research Articles
- Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells
Concurrent targeting of pyrimidine synthesis and oncogenic driver pathways improves therapeutic efficacy in glioblastoma.
- Lysozyme elicits pain during nerve injury by neuronal Toll-like receptor 4 activation and has therapeutic potential in neuropathic pain
Neuronal Toll-like receptor 4 activation by lysozyme enhances pain perception during nerve injury and emerges as neuron intrinsic axis to treat it.
- Intranasal micro-optical coherence tomography imaging for cystic fibrosis studies
Micro-optical coherence tomography with an intranasal imaging probe detects defects in the mucociliary transport of people with cystic fibrosis.
- Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model
Multispecific duoCAR-T cells potently suppress HIV infection in a humanized mouse model.
- Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
A robust personalized ctDNA test, TARDIS, achieves high accuracy for residual disease after completion of neoadjuvant therapy.
Editors' Choice
- Resolving deep vein thrombosis
Inflammation-resolving lipid mediator resolvin D4 attenuates murine venous thrombosis.
- Secreted frizzled-related protein 1 frazzles the brain in Alzheimer’s disease
Inhibition of ADAM10 α-secretase activity in neurons by secreted frizzled-related protein 1 may contribute to Alzheimer’s disease progression.
- Aging is just a state of marrow
Aging induces proliferation of bone marrow progenitor cells and disseminated tumor cells, leading to therapeutic resistance and bone metastasis.
About The Cover
ONLINE COVER Manipulating Metabolic Machinery. Mutation-specific drugs have shown some efficacy in reducing glioblastoma tumor growth; however, treatments do not eradicate glioblastoma stem cells (GSCs), a subpopulation of multipotent tumor cells responsible for drug resistance and tumor recurrence. This image summarizes in vivo data from Wang and colleagues, who tested a variety of treatments in mouse models of glioblastoma. After discovering that pyrimidine biosynthesis is increased in GSCs and contributes to GSC maintenance, Wang et al. combined mutation-specific therapies (left and right) with pyrimidine biosynthesis inhibition (middle). Combination therapy increased tumor cell death and improved survival in mice compared to either treatment alone. [CREDIT: LAN-TAO GOU]
